Latest Breaking News On - Jan skvarka - Page 2 : comparemela.com

Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Given Consensus Recommendation of "Buy" by Brokerages

Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Director Jan Skvarka Sells 5,000 Shares

Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL – Get Free Report) Director Jan Skvarka sold 5,000 shares of the stock in a transaction that occurred on Monday, September 11th. The stock was sold at an average price of $25.05, for a total transaction of $125,250.00. Following the transaction, the director now directly owns 47,970 shares of the company’s […]

Director Jan Skvarka Sells 5,000 Shares of Zentalis Pharmaceuticals Inc (ZNTL)

On September 11, 2023, Director Jan Skvarka sold 5,000 shares of Zentalis Pharmaceuticals Inc (NASDAQ:ZNTL).

Zentalis Pharmaceuticals : Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year - Form 8-K

Zntl-20230616 UNITED STATES . | June 16, 2023

Bloom Burton & Co. Inc.: Pieter Cullis Receives the 2022 Bloom Burton Award

Toronto, Ontario (Newsfile Corp. - September 30, 2022) - Bloom Burton & Co. ("Bloom Burton") is pleased to announce Pieter Cullis, Co-Founder of Acuitas Therapeutics, as the recipient of the 2022 Bloom